S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride,
vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by
killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled
monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and
carry cancer-killing substances to them without harming normal cells. Comparing results of
diagnostic procedures, such as PET scan and CT scan, done before, during, and after
chemotherapy may help doctors predict a patient's response to treatment and help plan the
best treatment.
PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating
patients with limited-stage diffuse large B-cell lymphoma.